Back to Search Start Over

Neurocrine's KarXT rival hits in phase 2 schizophrenia trial—but only at lowest dose.

Authors :
Taylor, Nick Paul
Source :
FierceBiotech; 8/28/2024, pN.PAG-N.PAG, 1p
Publication Year :
2024

Abstract

Neurocrine achieved its hoped-for profile in the schizophrenia trial but only saw efficacy at the lowest dose—the three higher doses all failed. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
SCHIZOPHRENIA
CLINICAL trials
DRUGS

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
179326068

Tools

Authors Abstract Subjects Details